Research & Education

Blood-Based Biomarkers to Guide Treatment of Advanced NSCLC

Monday, November 24, 2014 at 2:00PM EST - Recording Available

Blood-Based Biomarkers to Guide Treatment of Advanced NSCLC - November 24, 2014 at 2:00PM EST

David P. Carbone, MD, PhD
Barbara J. Bonner Chair in Lung Cancer Research
President-elect, International Association for the Study of Lung Cancer
Professor of Medicine
Director, James Thoracic Center
James Cancer Center
The Ohio State University Medical Center

Registration is taken on a first-come first served basis, participation is limited.

IASLC is holding a LIVE WEBINAR featuring Dr. David Carbone.

This webinar will explore recent advances in non-invasive procedures for biomarker testing to guide treatment of advanced NSCLC. Data will be presented reviewing DNA and protein level biomarkers that are measured in the blood of patients prior to treatment with standard of care therapeutics as well as for treatment monitoring. Guidance on how these measurements may be utilized to guide treatment decisions in both 1st and 2nd line treatment of advanced NSCLC will be explored.

Following a short, didactic presentation, Dr. Carbone will present a few case studies and thereafter ample time will be available for a question/answer session with the audience. Attendees will be able to submit questions and comments to Dr. Carbone via internet chat.

After attending this program, participants will:

  • be able to interpret data suggesting the utility of analysis of EGFR mutations from the plasma of patients with advanced NSCLC when re-biopsy material is insufficient or unobtainable.
  • be aware of developments in the use of serum-based proteomic assays for the prediction of differential treatment outcomes to 2nd line therapies in advanced NSCLC.
  • recognize where a serum-based proteomic assay may fit into clinical practice for the treatment of patients with NSCLC in the 2nd line setting
  • be able to discuss new information identifying the role of mutational analysis in plasma as a treatment monitoring tool for potential resistance mutations


CME INFO: Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar. If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.

This program is supported in part by an unrestricted educational grant from Biodesix Inc.